Loading clinical trials...

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland | Clinical Trials | Clareo Health

COMPLETED

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

NCT02846896•Fondazione Epatocentro Ticino

Summary

PBC is a rare, autoimmune, cholestatic liver disease with genetic and environmental pathogenetic factors. Data about epidemiology of PBC in Switzerland are completely lacking. Epidemiology can be a powerful tool in yielding important clues as to burden and etiology of diseases. In addition, the investigators study will be the first one carried out in the country on PBC, and therefore will raise disease awareness and create a network.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•PBC patients living in Switzerland

Exclusion Criteria

•\-

Locations (1)

Fondazione Epatocentro Ticino

Lugano, Switzerland

Key Dates

Start Date

December 1, 2015

Primary Completion Date

September 1, 2016

Completion Date

March 1, 2017

Last Updated

August 19, 2025

Enrollment

501

ACTUAL participants

Conditions

Primary Biliary Cirrhosis

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

NCT03301506

Primary Biliary Cirrhosis

View study

COMPLETEDPHASE2

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

NCT03112681

Primary Biliary Cirrhosis

View study

COMPLETEDPHASE1

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

NCT02963077

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

Inclusion Criteria

Exclusion Criteria

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine

Initial Study of Rituximab to Treat Primary Biliary Cirrhosis